Compare VELO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | VANI |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 91.9M |
| IPO Year | N/A | 2014 |
| Metric | VELO | VANI |
|---|---|---|
| Price | $18.13 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.8M | 267.2K |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,158,000.00 | N/A |
| Revenue This Year | $11.94 | N/A |
| Revenue Next Year | $56.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.44 | N/A |
| 52 Week Low | $1.43 | $0.91 |
| 52 Week High | $23.84 | $1.92 |
| Indicator | VELO | VANI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.37 |
| Support Level | N/A | $1.23 |
| Resistance Level | N/A | $1.35 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 66.20 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.